COUR Pharmaceuticals is developing a nanoparticle platform that reprograms the immune system to achieve antigen-specific tolerance in patients with immune-mediated diseases, such as multiple sclerosis and celiac disease. This approach targets the underlying causes of these conditions, moving beyond traditional therapies that primarily suppress symptoms.
Funding
Funding not disclosed
Founders
Product
Problem
Many current treatments for immune-mediated diseases, such as multiple sclerosis and celiac disease, only address the symptoms and rely on broad immune suppression, rather than targeting the underlying cause of the condition. These traditional approaches can have significant side effects and do not offer a long-term solution for patients.
Solution
COUR Pharmaceuticals is developing a novel nanoparticle platform designed to reprogram the immune system to achieve antigen-specific tolerance in patients with immune-mediated diseases. This approach aims to address the root cause of these conditions by inducing tolerance to specific antigens, rather than broadly suppressing the immune system. The nanoparticle platform has shown promise in both clinical and preclinical settings, demonstrating the potential to treat a wide range of immune and inflammatory conditions while preserving overall immune functionality. COUR's lead product for celiac disease, partnered with Takeda, represents the first demonstration of antigen-specific immune tolerance induction in any autoimmune disease.
Target Audience
The primary target audience includes patients suffering from immune-mediated diseases like multiple sclerosis and celiac disease, as well as pharmaceutical companies seeking innovative therapies in the immunology space.
Features
- Nanoparticle platform for antigen-specific immune tolerance induction
- Targeted reprogramming of the immune system
- Preservation of overall immune functionality
- Potential application across a range of immune and inflammatory conditions